Highly Profitable, FINRA-Registered Life Sciences Strategic Advisory & Investment Banking Firm
FINRA-Registered Life Sciences Advisory Firm with 16 Exclusive Clients
On NextCompany since August 27, 2026 (48 days)
Location undisclosedEstablished 2011
Business overview
Established in 2011, the FINRA-registered firm advises life sciences clients on M&A. It offers buy-side and sell-side services plus capital placement. The firm serves 16 active corporate clients under exclusive advisory agreements. No client exceeds 10 percent of revenue. The 2026 projection reaches $8,353,341 revenue with $3,674,067 EBITDA. Senior founders consider structured post-closing transition.
Who is a good fit for this business
- Buyers seeking FINRA-registered advisory firms focused on life sciences.
- Acquirers targeting businesses with 16 active corporate clients under exclusive agreements.
- Investors interested in advisory platforms with projected $3,674,067 EBITDA.
Details
Frequently Asked Questions
The firm provides buy-side and sell-side M&A, capital placement, asset divestitures, and strategic partnering advisory. It operates as a FINRA-registered Broker-Dealer. All active transaction team members hold required certifications.
The firm serves 16 active corporate clients under exclusive advisory agreements. No client exceeds 10 percent of revenue. The 2026 projection shows $8,353,341 revenue and $3,674,067 EBITDA.